ÇÇÀÓ¾à ½ÃÀå : ±âȸ, ÃËÁø¿äÀÎ, ¾÷°è µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1822646
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,872,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,573,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,832,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Global Market Insights Inc.°¡ ¹ßÇàÇÑ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ÇÇÀÓ¾à ½ÃÀåÀº 2024³â¿¡ 199¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGRÀº 8.4%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç 2025³â 211¾ï ´Þ·¯¿¡¼­ 2034³â¿¡ 438¾ï ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÇÇÀÓ¾à ¸¶ÄÏ-IMG1

»ý½Ä±Ç ¹× °¡Á· °èȹ¿¡ °üÇÑ °øÁß º¸°Ç Ä·ÆäÀΰú ±³À°ÀÌ È®´ëµÇ¸é¼­ ÇÇÀÓ¿¡ ´ëÇÑ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ºñÁ¤ºÎ±â±¸(NGO)¿Í Á¤ºÎ ±â°ü(¿¹ : UNFPA, WHO)Àº ¼±Áø±¹°ú °³¹ßµµ»ó±¹ ¸ðµÎ¿¡¼­ Çö´ëÀû ÇÇÀÓ¹ý Á¢±Ù¼ºÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀå ±Ô¸ð 199¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 438¾ï ´Þ·¯
CAGR 8.4%

ÀåÄ¡ äÅà Áõ°¡

ÀåÄ¡ ºÎ¹®Àº 2024³â Àå±â ÀÛ¿ë ¹× °¡¿ªÀû ÇÇÀÓ ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Àڱà ³» ÀåÄ¡(IUD), Äܵ¼, ÀÓÇöõÆ®¿Í °°Àº Á¦Ç°µéÀº È¿°ú¿Í ÆíÀǼºÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áß È£¸£¸ó ¹× ±¸¸® ±â¹Ý IUD´Â ³ôÀº ¼º°ø·ü°ú Àå±âÀû º¸È£ È¿°ú·Î ¿©ÀüÈ÷ ÃÖ¿ì¼± ¼±ÅÃÁöÀÔ´Ï´Ù. ½ÃÀå Âü¿©ÀÚµéÀº ´õ ³ÐÀº °í°´ÃþÀ» È®º¸Çϱâ À§ÇØ Á¦Ç° Çõ½Å, Çâ»óµÈ Âø¿ë°¨, »ç¿ë ±â°£ ¿¬Àå¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

15-44¼¼ÀÇ À¯º´·ü Áõ°¡

15-44¼¼ ºÎ¹®Àº »ý½Ä ¿¬·É´ëÀÌ¸ç °¡Á· °èȹ¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÕ´Ï´Ù.´Â Á¡¿¡¼­ 2024³â »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®Àº ÀӽŠÁö¿¬ ¿å±¸¿Í û¼Ò³â ¹× ÀþÀº ¼ºÀÎÃþÀÇ ¼º °Ç°­ ÀÎ½Ä Á¦°í Çʿ伺¿¡ ÀÇÇØ ÃËÁøµË´Ï´Ù. ±³À° È®´ë, µðÁöÅÐ Çコ Ç÷§Æû, Ÿ±ê ¸¶ÄÉÆÃ Ä·ÆäÀÎÀÌ ÀÌ Àα¸ Áý´Ü¿¡¼­ ÇÇÀÓ¹ý »ç¿ëÀ» Á¤»óÈ­ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¶óÀÌÇÁ½ºÅ¸ÀÏ ÀûÇÕ¼º, »ç¿ë ÆíÀǼº, Á¢±Ù¼ºÀ» °­Á¶ÇÏ¿© ÀÌ °í°´Ãþ°ú °ø°¨ÇÒ ¼ö ÀÖ´Â ¸Þ½ÃÁö¸¦ ¸ÂÃãÈ­Çϰí ÀÖ½À´Ï´Ù. ±¸µ¶ ¸ðµ¨°ú ºñ¹Ð ¹è¼Û ¼­ºñ½ºµµ ÀÌ ºÎ¹®ÀÇ »ç»ýȰ º¸È£ ÀǽÄÀÌ ³ôÀº »ç¿ëÀÚ¸¦ À¯Ä¡Çϱâ À§ÇØ µµÀԵǾú½À´Ï´Ù.

¼Ò¸Å ¾à±¹ ½ÃÀå ¼ºÀå °¡¼ÓÈ­

¼Ò¸Å ¾à±¹ ºÎ¹®Àº ÆíÀǼº, Á¢±Ù¼º, ¼ÒºñÀÚ ÀÍ¸í¼º ´öºÐ¿¡ 2025-2034³â µ¿¾È »ó´çÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀÔ´Ï´Ù. °æ±¸ ÇÇÀÓ¾à°ú ÀÀ±Þ ÇÇÀÓ¾àÀÇ ÀÏ¹Ý ÆÇ¸Å È®´ë¿¡ ÈûÀÔ¾î ÀÌ ºÎ¹®Àº ²ÙÁØÇÑ ¼ºÀå¼¼°¡ ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ¶ÇÇÑ ¿¬ÀåµÈ ¾à±¹ ¿î¿µ ½Ã°£, Áصµ½Ã Áö¿ª¿¡¼­ÀÇ Á¡À¯À² È®´ë, »ý½Ä °Ç°­ »ó´ã¿¡¼­ ¾à»çÀÇ ¿ªÇÒ Áõ°¡·Î ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ÁÖ¿ä ¼Ò¸Å Ã¼ÀÎÁ¡°ú ÆÄÆ®³Ê½ÊÀ» ü°áÇϰí, ÇÁ·Î¸ð¼Ç ÇÒÀÎÀ» Á¦°øÇϸç, Á¦Ç°ÀÇ Áö¼ÓÀûÀÎ °ø±ÞÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° ÀλçÀÌÆ®

ºÏ¹Ì°¡ À¯¸®ÇÑ Áö¿ªÀ¸·Î »ó½Â

ºÏ¹ÌÀÇ ÇÇÀÓ¾à ½ÃÀåÀº ³ôÀº ¼ÒºñÀÚ ÀνÄ, À¯¸®ÇÑ º¸Çè Àû¿ë Á¤Ã¥, °ß°íÇÑ ÀÇ·á ÀÎÇÁ¶ó¸¦ µÞ¹ÞħÀ¸·Î 2024³â »ó´çÇÑ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. È£¸£¸ó ÇÇÀÓ¾à, Àڱà ³» ÀåÄ¡(IUD), ÀÀ±Þ ÇÇÀÓ¾àÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ¸·Î ¹Ì±¹ÀÌ ÀÌ Áö¿ªÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ÃßÁ¤Ä¡¿¡ µû¸£¸é ºÏ¹Ì ½ÃÀåÀº 80¾ï ´Þ·¯ ÀÌ»óÀ¸·Î Æò°¡µÇ¾úÀ¸¸ç, µðÁöÅРó¹æÀü ¹× ¼ÒºñÀÚ Á÷Á¢ ÅÚ·¹Çコ ¼­ºñ½ºÀÇ °¡¿ë¼º Áõ°¡¿Í ÇÔ²² ²ÙÁØÈ÷ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼­ ¿î¿µµÇ´Â ±â¾÷µéÀº º¯È­ÇÏ´Â ¼ÒºñÀÚ Çൿ¿¡ ºÎÀÀÇϱâ À§ÇØ FDA ½ÂÀÎ, Á¦Ç° ´Ù°¢È­, ¿Â¶óÀÎ ÆÇ¸Å Ç÷§Æû È®´ë¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

ÇÇÀÓ¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº HLL Lifecare(Àεµ), È­ÀÌÀÚ, LifeStyles °Ç°­ °ü¸®, óġ & µå¿ÍÀÌÆ®, Exeltis, Reckitt, CooperSurgical, Medintim(Äɼ¿), Organon, Pregna International, Evofem Biosciences, Mayne Pharma, Agile Therapeu

ÇÇÀÓ¾à ½ÃÀå ±â¾÷µéÀº ÀÔÁö¸¦ À¯ÁöÇÏ°í ¼ºÀå½Ã۱â À§ÇØ Á¦Ç° Çõ½Å, Áö¿ª È®Àå, °í°´ Á᫐ Àü·«À» º¹ÇÕÀûÀ¸·Î Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. °¡Àå µÎµå·¯Áø Àü·« Áß Çϳª´Â ºñÈ£¸£¸ó ¹× ³²¼º¿ë ÇÇÀÓ ¿É¼ÇÀ» Æ÷ÇÔÇØ ´õ ¾ÈÀüÇϰí È¿°úÀûÀÎ, ±×¸®°í »ç¿ëÀÚ Ä£È­ÀûÀÎ Á¦Ç° °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß(R&D) ÅõÀÚÀÔ´Ï´Ù. ¶ÇÇÑ ºê·£µåµéÀº ÆíÀǼº ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ÅÚ·¹Çコ »ó´ã ¹× ¿Â¶óÀÎ ÁÖ¹® ó¸® ¼­ºñ½º¸¦ Á¦°øÇÏ¸ç µðÁöÅÐ Ç÷§ÆûÀ» ÅëÇÑ Á÷Á¢Àû °í°´ Á¢Á¡À» È®´ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Á¦Ç°º°(2021-2034³â)

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿¬·Éº°(2021-2034³â)

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : À¯Åë ä³Îº°(2021-2034³â)

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global contraceptives market was estimated at USD 19.9 billion in 2024 and is expected to grow from USD 21.1 billion in 2025 to USD 43.8 billion by 2034, at a CAGR of 8.4%, according to the latest report published by Global Market Insights Inc.

Contraceptives Market - IMG1

Growing public health campaigns and education around reproductive rights and family planning are increasing awareness and acceptance of contraceptives. NGOs and government initiatives (e.g., UNFPA, WHO) are promoting access to modern contraceptives in both developed and developing regions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$19.9 Billion
Forecast Value$43.8 Billion
CAGR8.4%

Rising Adoption of Devices

The devices segment held a notable share in 2024, driven by the growing demand for long-acting and reversible contraceptive options. Products such as intrauterine devices (IUDs), condoms, and implants are increasingly favored for their efficacy and convenience. Among these, hormonal and copper-based IUDs remain the top choices due to their high success rates and long-term protection. Market players are focusing on product innovation, enhanced comfort, and extended duration of use to attract a wider customer base.

Increasing Prevalence Among 15-44 Years

The 15-44 years segment held a sizeable share in 2024 owing to their reproductive age and active participation in family planning. This segment is driven by the desire to delay pregnancies and the rising need for sexual health awareness among adolescents and young adults. Increased educational outreach, digital health platforms, and targeted marketing campaigns are helping to normalize contraceptive use among this demographic. Companies are tailoring their messaging to resonate with this audience by emphasizing lifestyle compatibility, ease of use, and access. Subscription models and discreet delivery services have also been introduced to appeal to privacy-conscious users in this segment.

Retail Pharmacies to Gain Traction

The retail pharmacies segment will grow at a decent CAGR during 2025-2034, backed by convenience, accessibility, and anonymity to consumers. With the growing over-the-counter availability of oral contraceptives and emergency pills, this segment is witnessing steady growth. The segment also benefits from extended pharmacy hours, growing penetration in semi-urban areas, and pharmacists' increasing role in reproductive health counseling. To strengthen their presence, pharmaceutical companies are forming partnerships with major retail chains, offering promotional discounts, and ensuring consistent product availability.

Regional Insights

North America to Emerge as a Lucrative Region

North America contraceptives market generated significant revenues in 2024, supported by high consumer awareness, favorable reimbursement policies, and robust healthcare infrastructure. The United States leads the region due to the widespread adoption of hormonal contraceptives, IUDs, and emergency contraceptive pills. As of recent estimates, the market in North America was valued at over USD 8 billion and is projected to grow steadily with the increasing availability of digital prescriptions and direct-to-consumer telehealth services. Companies operating in this region are focused on FDA approvals, product diversification, and expanding their online sales platforms to meet evolving consumer behavior.

Major players in the contraceptives market are HLL Lifecare (India), Pfizer, LifeStyles Healthcare, Church & Dwight, Exeltis, Reckitt, CooperSurgical, Medintim (Kessel), Organon, Pregna International, Evofem Biosciences, Mayne Pharma, Agile Therapeutics, Bayer, HRA Pharma / Perrigo (OTC).

To maintain and grow their position, companies in the contraceptives market are employing a mix of product innovation, regional expansion, and customer-centric initiatives. One of the most prominent strategies involves investing in R&D to develop safer, more effective, and user-friendly products, including non-hormonal and male contraceptive options. Additionally, brands are leveraging digital platforms for direct engagement, offering telehealth consultations and online fulfillment services to meet the demand for convenience.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â